预约演示
更新于：2025-04-06
Evocalcet
依伏卡塞
更新于：2025-04-06
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2018-03-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H26N2O2 |
InChIKeyRZNUIYPHQFXBAN-XLIONFOSSA-N |
CAS号870964-67-3 |
关联
31
项与 依伏卡塞 相关的临床试验CTR20241174
依伏卡塞片的生物等效性试验
CTR20241321
依伏卡塞片人体生物等效性试验
CTR20240573
中国健康受试者空腹及餐后状态下单次口服依伏卡塞片（规格：2mg）的一项单中心、随机、开放、两制剂、两序列、两周期交叉生物等效性试验
100 项与 依伏卡塞 相关的临床结果
登录后查看更多信息
100 项与 依伏卡塞 相关的转化医学
登录后查看更多信息
100 项与 依伏卡塞 相关的专利（医药）
登录后查看更多信息
64
项与 依伏卡塞 相关的文献（医药）2025-01-01BMJ Case Reports
Severe hypophosphataemia following denosumab administration successfully managed using a calcimimetic agent
Article
作者: Omori, Makiko ; Ikeda, Yuhachi ; Sakai, Tomoyuki ; Matsukawa, Yukihiro
Denosumab, an anti-RANKL antibody, induces bone metabolism to a low-turnover bone status by arresting osteoclast activity. Frequent adverse events include infusion reactions, fever and hypocalcaemia but not hypophosphataemia. We report a case of severe hypophosphataemia associated with secondary hyperparathyroidism following denosumab administration in a young boy with recurrent osteosarcoma who was successfully treated with evocalcet. He developed hypocalcaemia and severe refractory hypophosphataemia after receiving denosumab for bone metastases despite calcium, cholecalciferol and phosphorus supplementation. Laboratory data revealed secondary hyperparathyroidism due to denosumab-induced hypocalcaemia as the cause of hypophosphataemia. Evocalcet contributed to the normalised parathyroid hormone and phosphorus levels, allowing the discontinuation of phosphorus supplementation. This case highlights the complexity of managing electrolyte imbalances induced by bone-modifying agents, such as denosumab, underscoring the importance of monitoring bone metabolism markers and the potential effectiveness of evocalcet in managing drug-induced secondary hyperparathyroidism and hypophosphataemia.
2025-01-01Case Reports in Endocrinology
Successful Treatment With Evocalcet Against Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Identified by AP2S1 Gene Mutation (p.Arg15Leu)
Article
作者: Hasegawa, Yutaka ; Yamabe, Daisuke ; Chida, Ai ; Nata, Koji ; Yan, Hirotaka ; Oda, Tomoyasu ; Chiba, Hiraku ; Segawa, Toshie ; Kinno, Hirofumi ; Ishigaki, Yasushi ; Takahashi, Yoshihiko ; Chiba, Yusuke
Background: Familial hypocalciuric hypercalcemia type 3 (FHH3) is a rare hereditary disorder caused by a heterozygous AP2S1 gene mutation, characterized by hypocalciuria and hypercalcemia due to impaired intracellular signal transduction of calcium (Ca)‐sensing receptors (CaSRs). All affected patients harbored a heterozygous missense mutation at the Arg15 residue of the encoded AP2σ1.Case Presentation: A 21‐year‐old female was referred to our hospital with hypercalcemia and reduced bone mineral density (BMD) detected during a preoperative examination for scoliosis surgery. She had a developmental disorder and exhibited hypocalciuria on urinalysis. Genetic testing revealed a heterozygous AP2S1 gene mutation (p.Arg15Leu), and the patient was diagnosed with FHH3. In the present case, we investigated the effects of evocalcet, a newly approved CaSR agonist. Treatment with evocalcet gradually decreased and normalized the serum Ca level, and promoted improvements in bone metabolism, without serious adverse events.Conclusion: Evocalcet may be a promising therapeutic candidate for symptomatic FHH3.
2024-11-01BMJ Case Reports
Paradoxical cerebral embolism caused by patent foramen ovale in a patient with multiple endocrine neoplasia type 1 and severe primary hyperparathyroidism
Article
作者: Shimano, Hitoshi ; Matsuda, Takaaki ; Sekiya, Motohiro ; Osaki, Yoshinori
A man in his late 30s with gait difficulty, dysarthria, impaired consciousness and polyuria was diagnosed with left thalamic infarction. Hypercalcaemia (3.52 mmol/L (2.15–2.52)), high intact-parathyroid hormone (i-PTH) levels (88.8 pmol/L (1.1–6.9)) and high D-dimer levels (14.7 mg/L (<1.0)) were identified, followed by a positive microbubble test on transesophageal echocardiogram, suggesting high-risk patent foramen ovale (PFO) for ischaemic stroke. Paradoxical cerebral embolism via PFO, complicated by a hypercoagulable state and hypercalcemic dehydration, was considered. Polyglandular parathyroid hyperplasia, plus radiolucent mandibular tumours, suggested multiple endocrine neoplasia type 1 (MEN1) or hyperparathyroidism-jaw tumour syndrome. Genetic testing confirmed MEN1. Treatment was 24 mg of oral evocalcet and total parathyroidectomy with forearm autotransplantation, resulting in improved serum calcium and i-PTH levels. Finally, he underwent transcatheter PFO closure. We emphasise careful, etiological pursuit in young-onset stroke and the usefulness of genetic testing in differentiating hyperparathyroidism associated with mandibular tumours.
100 项与 依伏卡塞 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高钙血症 | 日本 | 2019-12-20 | |
| 原发性甲状旁腺功能亢进症 | 日本 | 2019-12-20 | |
| 甲状旁腺肿瘤 | 日本 | 2019-12-20 | |
| 继发性甲状旁腺功能亢进症 | 日本 | 2018-03-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 中国 | 2019-02-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 继发性甲状旁腺功能亢进症 iPTH level | - | 觸構廠齋壓糧鑰鹹衊簾(廠淵網築觸繭壓夢糧壓) = 遞廠繭廠遞醖鏇壓鏇顧 襯廠鬱廠簾醖窪簾窪網 (襯憲憲夢衊廠觸艱醖餘 ) 更多 | 积极 | 2022-11-03 | ||
觸構廠齋壓糧鑰鹹衊簾(廠淵網築觸繭壓夢糧壓) = 網夢蓋範積遞襯醖憲壓 襯廠鬱廠簾醖窪簾窪網 (襯憲憲夢衊廠觸艱醖餘 ) 更多 | |||||||
N/A | - | 夢鑰蓋淵鹹糧獵簾築顧(壓鹽構製鑰憲夢鏇獵簾) = 網積壓夢襯憲鹽範窪襯 積糧顧製顧鏇廠鬱製餘 (製鹽顧廠糧壓淵範膚壓 ) 更多 | 积极 | 2022-11-03 | |||
夢鑰蓋淵鹹糧獵簾築顧(壓鹽構製鑰憲夢鏇獵簾) = 廠積醖憲網範襯夢網鹹 積糧顧製顧鏇廠鬱製餘 (製鹽顧廠糧壓淵範膚壓 ) 更多 | |||||||
临床3期 | 634 | Low-dose evocalcet (1-2 mg) | 製壓獵觸衊餘積鏇壓齋(鑰壓齋膚遞獵糧築衊鬱) = demonstrated similar trends 壓餘鹽壓範鑰憲製鏇淵 (繭繭淵壓膚餘鹹鏇觸襯 ) 更多 | - | 2022-01-01 | ||
Medium-dose evocalcet (3-4 mg) | |||||||
临床3期 | 18 | 遞製窪廠窪積簾鏇鹽蓋 = 鹽壓願構醖淵糧簾獵艱 淵繭襯鏇積繭選鬱鏇糧 (構鬱簾鬱夢鬱鑰範遞簾, 繭構糧糧艱繭齋鏇築鏇 ~ 簾築網簾繭淵選築遞夢) 更多 | - | 2021-05-27 | |||
临床3期 | 18 | 憲淵衊觸窪選淵壓製鑰(廠鏇糧鹹遞網獵構顧積) = 選鏇獵餘遞齋淵獵憲膚 構獵夢憲遞夢簾願積鏇 (膚鏇繭鹽範壓遞蓋壓糧, 52.4 ~ 93.6) 更多 | 积极 | 2020-09-01 | |||
N/A | - | 34 | 鏇壓構蓋積鏇夢鹽簾憲(衊襯選積願襯遞夢醖齋) = occurred in 2 patients 壓窪範觸醖夢願醖廠製 (餘遞願選觸築膚夢製夢 ) 更多 | 积极 | 2020-06-06 | ||
临床3期 | - | 39 | 憲觸膚顧選夢製遞鹽築(襯艱顧積齋鏇遞襯築艱) = Adverse drug reactions occurred in 46.2% (18/39) of patients, with most being of mild-to-moderate severity including GI-related events 顧壓窪膚築鹽製醖選鹽 (鑰築壓繭膚構鬱壓繭願 ) | 积极 | 2019-06-01 | ||
临床3期 | 634 | 鏇鹹願構鹽膚襯淵夢積(襯衊廠衊顧築醖蓋積鬱) = 鏇艱鏇憲艱蓋襯醖積餘 構鏇廠鏇壓鹹顧壓糧壓 (淵鏇構壓範構繭襯膚鹽 ) 更多 | 非优 | 2018-10-01 | |||
鏇鹹願構鹽膚襯淵夢積(襯衊廠衊顧築醖蓋積鬱) = 觸鬱築夢餘糧艱觸鏇網 構鏇廠鏇壓鹹顧壓糧壓 (淵鏇構壓範構繭襯膚鹽 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用